275 related articles for article (PubMed ID: 35245004)
1. Major clinical research advances in gynecologic cancer in 2021.
Park JY; Lee JY; Lee YY; Shim SH; Suh DH; Kim JW
J Gynecol Oncol; 2022 Mar; 33(2):e43. PubMed ID: 35245004
[TBL] [Abstract][Full Text] [Related]
2. Major clinical research advances in gynecologic cancer in 2020.
Lee YY; Choi MC; Park JY; Suh DH; Kim JW
J Gynecol Oncol; 2021 Jul; 32(4):e53. PubMed ID: 34085794
[TBL] [Abstract][Full Text] [Related]
3. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
4. Major clinical research advances in gynecologic cancer in 2017.
Suh DH; Kim M; Lee KH; Eom KY; Kjeldsen MK; Mirza MR; Kim JW
J Gynecol Oncol; 2018 Mar; 29(2):e31. PubMed ID: 29468855
[TBL] [Abstract][Full Text] [Related]
5. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3.
Lee JY; Lee YY; Park JY; Shim SH; Kim SI; Kong TW; Lim CK; Cho HW; Suh DH
J Gynecol Oncol; 2023 Mar; 34(2):e51. PubMed ID: 36890294
[TBL] [Abstract][Full Text] [Related]
6. Major clinical research advances in gynecologic cancer in 2019.
Kim M; Suh DH; Lee KH; Eom KY; Lee JY; Lee YY; Hansen HF; Mirza MR; Kim JW
J Gynecol Oncol; 2020 May; 31(3):e48. PubMed ID: 32319232
[TBL] [Abstract][Full Text] [Related]
7. Major clinical research advances in gynecologic cancer in 2018.
Kim M; Suh DH; Lee KH; Eom KY; Toftdahl NG; Mirza MR; Kim JW
J Gynecol Oncol; 2019 Mar; 30(2):e18. PubMed ID: 30806045
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
[TBL] [Abstract][Full Text] [Related]
10. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
[TBL] [Abstract][Full Text] [Related]
13. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Pan K; Gong J; Huynh K; Cristea M
Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
[TBL] [Abstract][Full Text] [Related]
14. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
[TBL] [Abstract][Full Text] [Related]
15. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
16. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
17. [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
Marom I; Lavie O; Ostrovsky L; Kugelman N; Schmidt M; Segev Y
Harefuah; 2020 Mar; 159(3):175-180. PubMed ID: 32186787
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
19. The systemic treatment of recurrent ovarian cancer revisited.
Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
